Navigation Links
InterMune to Present Abstracts on HCV Protease Inhibitor ITMN-191 and HCV Development Program at the EASL Meeting
Date:3/18/2009

available HCV NS3/4A Inhibitors that Display Unimpaired Activity Against an NS3 Sequence Variant Associated with Resistance to Linear Tetrapeptides and Macrocyclic Inhibitors.
  • A Mouse Model with Long Term Expression of Hepatitis C Virus NS3/4A Protease for the Pharmacokinetic and Pharmacodynamic (PK-PD) Study of HCV Protease Inhibitors
  • About EASL

    The European Association for the Study of the Liver (EASL) is the leading European association in the field of liver research. EASL brings together clinicians and scientists interested in the liver, providing an outlet for networking and learning. The EASL Annual Meeting attracts more than 7,000 participants annually.

    About InterMune

    InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes the Phase 3 program, CAPACITY, which is evaluating pirfenidone as a possible therapeutic candidate for the treatment of patients with IPF and a research program focused on pirfenidone analog ITMN-520. The hepatology portfolio includes the HCV protease inhibitor compound ITMN-191 (referred to as R7227 at Roche) expected to enter Phase 2b in the summer of 2009, a second-generation HCV protease inhibitor research program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.

    Forward-Looking Statements

    This news release contains forward-looking statements within the meaning of section 21E of the Securities Exchange Act of 1934, as amended, that reflect InterMune's judgment and
    '/>"/>

    SOURCE InterMune, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3

    Related biology technology :

    1. InterMune Reports Fourth Quarter and Full Year 2008 Financial Results and Business Highlights
    2. InterMune to Release Fourth Quarter, Full Year 2008 Financial Results on February 26
    3. InterMune Announces Issuance of U.S. Patent for ITMN-191
    4. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
    5. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
    6. InterMune to Present at J.P. Morgan Healthcare Conference
    7. InterMune to Present at Deutsche Bank Biotech Boston Confab
    8. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
    9. InterMune to Release Third Quarter 2008 Financial Results on November 6
    10. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
    11. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... More than 5 million Americans are ... 3 seniors will die with Alzheimer’s or another dementia, ... have shocked many Americans into looking for ways to ... tragic age-related cognitive disorders. Jonathan Weisman, president of Biohack ...
    (Date:1/15/2014)... Freeslate, Inc ., the leading ... Lupin Limited, one of India’s top five pharmaceutical companies, ... System for high throughput solid form screening. ... a wide range of quality, affordable generic and branded ...
    (Date:1/14/2014)... January 14, 2014 Histogen, Inc., a ... of cells grown under simulated embryonic conditions, today announced ... with Suneva Medical, Inc. for physician-dispensed aesthetic products containing ... , This agreement is an amendment to the existing ...
    (Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014 ... two institutes from the National Institutes of Health (NIH) ... safer, more effective treatments to patients on a faster ... Advancing Translational Sciences (NCATS) and the National Eye Institute ...
    Breaking Biology Technology:Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 2Histogen and Suneva Medical Expand License for Cell Conditioned Media-based Aesthetic Products Internationally 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3
    ... Reportlinker.com announces that a new market research report is ... - technologies, markets and companies ... Up-to-date on-stop information on gene therapy with 72 tables and ... - 700 selected references from the literature ...
    ... announces that a new market research report is ... applications, markets and companies ... creation and utilization of materials, devices, and systems ... scale (a nanometer is one billionth of a ...
    ... strip with two surfaces but only one side, has been ... German mathematician August Mbius. As artist M.C. Escher so vividly ... traverse the "inside" and "outside" surfaces of a Mbius strip ... searching for an example of Mbius symmetry in natural materials ...
    Cached Biology Technology:Reportlinker Adds Gene Therapy - technologies, markets and companies 2Reportlinker Adds Gene Therapy - technologies, markets and companies 3Reportlinker Adds Gene Therapy - technologies, markets and companies 4Reportlinker Adds Gene Therapy - technologies, markets and companies 5Reportlinker Adds Gene Therapy - technologies, markets and companies 6Reportlinker Adds Gene Therapy - technologies, markets and companies 7Reportlinker Adds Gene Therapy - technologies, markets and companies 8Reportlinker Adds Gene Therapy - technologies, markets and companies 9Reportlinker Adds Gene Therapy - technologies, markets and companies 10Reportlinker Adds Gene Therapy - technologies, markets and companies 11Reportlinker Adds Gene Therapy - technologies, markets and companies 12Reportlinker Adds Gene Therapy - technologies, markets and companies 13Reportlinker Adds Gene Therapy - technologies, markets and companies 14Reportlinker Adds Gene Therapy - technologies, markets and companies 15Reportlinker Adds Gene Therapy - technologies, markets and companies 16Reportlinker Adds Gene Therapy - technologies, markets and companies 17Reportlinker Adds Gene Therapy - technologies, markets and companies 18Reportlinker Adds Gene Therapy - technologies, markets and companies 19Reportlinker Adds Gene Therapy - technologies, markets and companies 20Reportlinker Adds Gene Therapy - technologies, markets and companies 21Reportlinker Adds Nanobiotechnologies- applications, markets and companies 2Reportlinker Adds Nanobiotechnologies- applications, markets and companies 3Reportlinker Adds Nanobiotechnologies- applications, markets and companies 4Reportlinker Adds Nanobiotechnologies- applications, markets and companies 5Reportlinker Adds Nanobiotechnologies- applications, markets and companies 6Reportlinker Adds Nanobiotechnologies- applications, markets and companies 7Reportlinker Adds Nanobiotechnologies- applications, markets and companies 8Reportlinker Adds Nanobiotechnologies- applications, markets and companies 9Reportlinker Adds Nanobiotechnologies- applications, markets and companies 10Reportlinker Adds Nanobiotechnologies- applications, markets and companies 11Reportlinker Adds Nanobiotechnologies- applications, markets and companies 12Reportlinker Adds Nanobiotechnologies- applications, markets and companies 13Reportlinker Adds Nanobiotechnologies- applications, markets and companies 14Reportlinker Adds Nanobiotechnologies- applications, markets and companies 15Reportlinker Adds Nanobiotechnologies- applications, markets and companies 16
    (Date:7/9/2014)... of increasing concern about the prevalence of antibiotic-resistant ... promising new pathway to disabling disease: blocking bacteria,s ... scientists showed how bacterial siderophore, a small molecule, ... fan bacterial growth as well as how ... infection process. Their findings appear in a recent ...
    (Date:7/9/2014)... season upon us, many backyard cooks are turning to ... dogs. But low fat can sometimes mean low satisfaction. ... texture problem in low-fat wieners that are made with ... published in ACS, Journal of Agricultural and Food ... that hot-dog consumers have come to expect just the ...
    (Date:7/9/2014)... re-examination of a sparrow-sized fossil from China challenges the ... dinosaurs that gained the ability to fly. The birdlike ... but much rather the remains of a tiny tree-climbing ... of the Dinosaur Museum in Blanding, Utah, and Alan ... appears in Springer,s Journal of Ornithology . , ...
    Breaking Biology News(10 mins):Bacteria hijack plentiful iron supply source to flourish 2Researchers declassify dinosaurs as being the great-great-grandparents of birds 2
    ... always been what they are today, particularly for omnivores. ... tigers and other big cats as examples. Other mammals ... on a diet of leaves, shoots, fruits and bark. ... addition to meat, the situation wasn,t always that way, finds ...
    ... , This release is available in ... the US and Europe harbour more plant species than ... closer related to each other and often share similar ... environmental impacts than rural ecosystems. This is concluded by ...
    ... 18/04/12 - Technology has transformed the way humans interact with ... ideas that will drive growth in marine and maritime sectors ... policy will gather at the 3rd Marine Board Forum in ... Board has convened this flagship event on the understanding that ...
    Cached Biology News:Scientists trace evolutionary history of what mammals eat 2Live fast, die young 2New technologies for a blue future 2
    Eagle's Ham's amino acids; EHAA...
    ... IRsolution software provides quick and easy operation ... with Windows-based control. The software is ... FDA 21 CFR Part 11 regulations, and ... measurement. IRsolutions versatility enables use in ...
    ... introduce random mutations to the gene supplied by ... into a vector of choice to obtain a ... can be set to a desired value within ... 106-108. Mutations can be restricted to a ...
    ... EVOlyzer is Tecans new Enzyme-Linked Immunosorbent Assay ... Freedom EVOlyzer is a dedicated EVO platform ... reader, washer and incubation units operated by ... EVOlyzer is available in three sizes - ...
    Biology Products: